K. A. Williams, . Sr, J. D. Williamson, J. T. Wright, and . Jr, , 2017.

, PCNA Guideline for the Prevention, p.349

, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A 350 Report of the American College of Cardiology, American Heart Association Task Force on Clinical, p.351

, Practice Guidelines. Circulation, vol.138, issue.17, pp.426-483, 2018.

S. L. Daugherty, J. D. Powers, D. J. Magid, H. M. Tavel, F. A. Masoudi et al., Incidence and prognosis of resistant hypertension in 354 hypertensive patients, Circulation, vol.353, issue.13, pp.1635-1677

F. L. Mondesir, T. M. Brown, P. Muntner, R. W. Durant, A. P. Carson et al., , p.356

E. B. Levitan, Diabetes, diabetes severity, and coronary heart disease risk equivalence: REasons for 357 Geographic and Racial Differences in Stroke (REGARDS), Am Heart J, vol.181, pp.43-51, 2016.

S. F. Rimoldi, F. H. Messerli, S. Bangalore, U. Scherrer, B. Zinman et al., Resistant hypertension: what the 359 cardiologist needs to know, Eur Heart J, vol.36, issue.40, 2015.

T. Devins, O. E. Johansen, H. J. Woerle, U. C. Broedl, and S. E. Inzucchi, Empagliflozin, Cardiovascular 362 Outcomes, and Mortality in Type 2 Diabetes. The New England journal of medicine, vol.363, p.11, 2015.

M. Azizi, P. Rossignol, and J. S. Hulot, Emerging Drug Classes and Their Potential Use in
URL : https://hal.archives-ouvertes.fr/hal-02512565

I. Tikkanen, K. Narko, C. Zeller, A. Green, A. Salsali et al., Hypertension. Hypertension, p.366, 2019.

, Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes 367 Care, vol.38, pp.420-428, 2015.

G. Mancia, C. P. Cannon, I. Tikkanen, C. Zeller, L. Ley et al., , p.369

O. E. Johansen, Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus 370 and Hypertension by Background Antihypertensive Medication, Hypertension, issue.6, pp.1355-1364, 1979.

D. Z. Cherney, B. A. Perkins, N. Soleymanlou, R. Har, N. Fagan et al., , p.373

H. J. Von-eynatten, M. Broedl, and U. C. , The effect of empagliflozin on arterial stiffness and heart rate 374 variability in subjects with uncomplicated type 1 diabetes mellitus, Cardiovasc Diabetol, vol.13, p.15, 2014.

R. Chilton, I. Tikkanen, C. P. Cannon, S. Crowe, H. J. Woerle et al.,

E. Inzucchi, S. E. Zinman, B. Fitchett, D. Wanner, C. Ferrannini et al., Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular 377 resistance in patients with type 2 diabetes, Diabetes Obes Metab, vol.17, issue.12, pp.1180-93, 2015.

C. Schmoor, K. Ohneberg, O. E. Johansen, J. T. George, S. Hantel et al., , p.380

, How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the

E. Trial, Diabetes Care, vol.41, issue.2, pp.356-363, 2018.

G. Bayliss, L. A. Weinrauch, and J. A. Elia, Resistant hypertension in diabetes mellitus, Curr, vol.383

D. Rep-;-chobanian, A. V. Bakris, G. L. Black, H. R. Cushman, W. C. Green et al., , vol.14, pp.516-384, 2014.

D. W. Jones, B. J. Materson, S. Oparil, J. T. Wright, . Jr et al.,

, Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood 387 Pressure: the JNC 7 report, vol.289, pp.2560-72, 2003.

W. C. Cushman, G. W. Evans, R. P. Byington, D. C. Goff, . Jr et al., , p.389

D. G. Simons-morton, J. N. Basile, M. A. Corson, J. L. Probstfield, L. Katz et al., , p.390

W. T. Friedewald, J. B. Buse, J. T. Bigger, H. C. Gerstein, and F. Ismail-beigi, Effects of intensive 391 blood-pressure control in type 2 diabetes mellitus. The New England journal of medicine, vol.362, pp.1575-85, 2010.

X. Xie, E. Atkins, J. Lv, A. Bennett, B. Neal et al.,

S. Turnbull, F. Hillis, G. S. Chalmers, J. Mant, J. Salam et al., 395 Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated 396 systematic review and meta-analysis, Lancet, vol.387, p.21, 2016.

R. Aggarwal, J. Steinkamp, N. Chiu, B. Petrie, and H. Mirzan, Intensive Blood Pressure 398 Targets for Diabetic and Other High-Risk Populations: A Pooled Individual Patient Data Analysis

, Hypertension, vol.71, issue.5, pp.833-839, 1979.

J. T. Wright, . Jr, J. D. Williamson, P. K. Whelton, J. K. Snyder et al., , vol.401

D. M. Reboussin, M. Rahman, S. Oparil, C. E. Lewis, P. L. Kimmel et al., , vol.402

L. J. Fine, J. A. Cutler, W. C. Cushman, A. K. Cheung, and W. T. Ambrosius, A Randomized Trial of 403 Intensive versus Standard Blood-Pressure Control, The New England journal of medicine, vol.373, issue.22, pp.2103-2119, 2015.

, Resistant hypertension" was a post-hoc presumptive diagnosis. ACE indicates angiotensin-converting enzyme

, BMI (category), eGFR (category), treatment, rHT, and treatment by resistant hypertension interaction, *HR by multivariable Cox regression with the following variables: age, sex, region, HbA1c (category)

, way interactions as fixed effects (for details on other fixed effects and linear covariates, see "statistical analysis" section)